Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Tumor-Agnostic 1

Conditions

Recurrence 1Neoplasm Metastasis 1Glioblastoma 1Astrocytoma 1

Interventions

Specimen Handling 454Magnetic Resonance Spectroscopy 347pembrolizumab 289Biopsy 244Carboplatin 230Cisplatin 194Cyclophosphamide 186Paclitaxel 164Nivolumab 154Gemcitabine 151Radiotherapy 125Bevacizumab 124Dexamethasone 113fludarabine 100Pemetrexed 99Fluorouracil 94Doxorubicin 92durvalumab 91Radiation 91Docetaxel 91venetoclax 89Rituximab 88Oxaliplatin 88atezolizumab 87Leucovorin 79Capecitabine 76Prednisone 75Lenalidomide 70Etoposide 69X-Rays 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
AZD1390 × 30 days × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT05678010 2026-05-18

A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
54 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06894979 2026-05-15

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Children's Oncology Group

Phase 1 Recruiting
54 enrolled
CNS

Astrocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡